The binding of therapeutic antibodies to CD64 is of particular interest, as CD64+ myeloid cells producing IL-23 are increased in the inflamed colon in IBD, and this binding might potentially enhance IL-23 blockade. This evidence concerns the gene IL23A and inflammatory bowel disease.